307 related articles for article (PubMed ID: 3938590)
1. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
Kuzmits R; Scheithauer W; Ludwig H; Flener R
Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
3. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
Kempf RA; Grunberg SM; Daniels JR; Skinner DG; Venturi CL; Spiegel R; Neri R; Greiner JM; Rudnick S; Mitchell MS
J Biol Response Mod; 1986 Feb; 5(1):27-35. PubMed ID: 3958753
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.
Bruntsch U; de Mulder PH; ten Bokkel Huinink WW; Clavel M; Drozd A; Kaye SB; Renard J; van Glabbeke M
J Biol Response Mod; 1990 Jun; 9(3):335-8. PubMed ID: 2116500
[TBL] [Abstract][Full Text] [Related]
7. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of renal cell carcinoma. 3. Interferon therapy].
Kobayashi M; Imai K; Kiren H; Nakai K; Saruki K; Umeyama T; Ito Y; Yamanaka H; Makino T; Machida M
Hinyokika Kiyo; 1987 Apr; 33(4):508-14. PubMed ID: 3618421
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma.
Scheithauer W; Kuehrer I; Kutzmits R; Dittrich C; Steger G; Flener R; Ludwig H
J Biol Regul Homeost Agents; 1987; 1(2):81-6. PubMed ID: 3504086
[TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
11. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Figlin RA; deKernion JB; Maldazys J; Sarna G
Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F
J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838
[TBL] [Abstract][Full Text] [Related]
13. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
Rinehart JJ; Malspeis L; Young D; Neidhart JA
J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors.
Canobbio L; Curotto A; Cannata D; Miglietta L; Lavarello A; Giglio C; Franchini R; Cussotto M; Boccardo F
Anticancer Res; 1996; 16(1):541-4. PubMed ID: 8615668
[TBL] [Abstract][Full Text] [Related]
18. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
19. Interferon in metastatic renal cell carcinoma.
Fosså SD
Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]